China, Nov. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase II Clinical Trial of CAPOX plus Bevacizumab Induction Followed by Concurrent Sintilimab and Ipilimumab N01 as Conversion Therapy for RAS-Mutant or Right-Sided Primary MSS/pMMR Colorectal Cancer Liver Metastases'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600136582

Registration Time: 2026/11/12

Type: Interventional study

Primary Sponsor: Department of General Surgery ,First Medical Center of Cninese PLA General Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=345349

Published by HT Digital Content Services with permission from Health D...